Monalizumab (formerly IPH2201) blocks the inhibitory signaling induced by NKG2A/CD94 expressed on NK cells, restoring the anti-tumor response mediated by NK cells in hematological malignancies [30,61,111,112,113]. The gene discussed is KLRC1; the disease is neoplasm.